Literature DB >> 30257808

Strength of the association between antibiotic use and hemolytic uremic syndrome following Escherichia coli O157:H7 infection varies with case definition.

Gillian A M Tarr1, Hanna N Oltean2, Amanda I Phipps3, Peter Rabinowitz4, Phillip I Tarr5.   

Abstract

BACKGROUND: The veracity of the association between antibiotic use and hemolytic uremic syndrome (HUS) caused by Escherichia coli O157:H7 has been a topic of debate. We postulated that criteria used to define HUS affect this association.
METHODS: We reviewed 471 hospitalized E. coli O157:H7 cases reported in Washington State, 2005-2014, to determine HUS status by various case definitions and antibiotic treatment. We used age-adjusted logistic regression models to estimate the effect of treatment on HUS status according to four common, but heterogeneous, definitions: the Council of State and Territorial Epidemiologists (CSTE) definition, hematology-focused and age-focused definitions from the literature, and hospital diagnosis.
RESULTS: Inter-annual variation in antibiotic use was high, but no meaningful change in antibiotic use was observed over this ten-year period. Thirteen percent of cases <18 years-old received antibiotics, compared to 54% of cases ≥18 years-old. The CSTE, hematology-focused, age-focused, and hospital diagnosis definitions identified 149, 57, 74, and 89 cases of HUS, respectively. The association between antibiotic treatment and HUS varied by definition: CSTE odds ratio (OR) 1.57 [95% confidence interval (CI) 0.98, 2.55]; hematology-focused OR 1.73 (95% CI 0.83, 3.54); age-focused OR 2.29 (95% CI 1.20, 4.39); and hospital diagnosis OR 1.94 (95% CI 1.01, 3.72).
CONCLUSIONS: Each definition yielded an estimate of the association in the direction of increased risk of HUS with antibiotics. While the range of OR point estimates was relatively small, confidence intervals for two HUS definitions crossed the null and two did not, potentially altering the inference an investigator makes. Discrepant reports of the association between antibiotic use and HUS in the literature might be due in part to the choice of HUS definition, and a consistent definition of HUS should be adopted for research and public health purposes.
Copyright © 2018 Elsevier GmbH. All rights reserved.

Entities:  

Keywords:  Antibiotics; E. coli O157:H7; Hemolytic uremic syndrome; Shiga toxin-producing Escherichia coli

Mesh:

Substances:

Year:  2018        PMID: 30257808      PMCID: PMC6287940          DOI: 10.1016/j.ijmm.2018.06.009

Source DB:  PubMed          Journal:  Int J Med Microbiol        ISSN: 1438-4221            Impact factor:   3.473


  31 in total

1.  Escherichia coli O157:H7 and the hemolytic uremic syndrome: importance of early cultures in establishing the etiology.

Authors:  P I Tarr; M A Neill; C R Clausen; S L Watkins; D L Christie; R O Hickman
Journal:  J Infect Dis       Date:  1990-08       Impact factor: 5.226

2.  Province-Wide Review of Pediatric Shiga Toxin-Producing Escherichia coli Case Management.

Authors:  Stephen B Freedman; Mohamed Eltorki; Linda Chui; Jianling Xie; Sharon Feng; Judy MacDonald; Andrew Dixon; Samina Ali; Marie Louie; Bonita E Lee; Lara Osterreicher; Jennifer Thull-Freedman
Journal:  J Pediatr       Date:  2016-10-10       Impact factor: 4.406

3.  Shiga toxin activatable by intestinal mucus in Escherichia coli isolated from humans: predictor for a severe clinical outcome.

Authors:  Martina Bielaszewska; Alexander W Friedrich; Thomas Aldick; Robin Schürk-Bulgrin; Helge Karch
Journal:  Clin Infect Dis       Date:  2006-10-02       Impact factor: 9.079

Review 4.  Enterohaemorrhagic Escherichia coli in human medicine.

Authors:  Helge Karch; Phillip I Tarr; Martina Bielaszewska
Journal:  Int J Med Microbiol       Date:  2005-10       Impact factor: 3.473

5.  Sporadic cases of haemolytic-uraemic syndrome associated with faecal cytotoxin and cytotoxin-producing Escherichia coli in stools.

Authors:  M A Karmali; B T Steele; M Petric; C Lim
Journal:  Lancet       Date:  1983-03-19       Impact factor: 79.321

6.  Shiga toxin-producing Escherichia coli in children with diarrhea: a prospective point-of-care study.

Authors:  Eileen J Klein; Jennifer R Stapp; Carla R Clausen; Daniel R Boster; Joy G Wells; Xuan Qin; David L Swerdlow; Phillip I Tarr
Journal:  J Pediatr       Date:  2002-08       Impact factor: 4.406

7.  Incidence and Trends of Infections with Pathogens Transmitted Commonly Through Food and the Effect of Increasing Use of Culture-Independent Diagnostic Tests on Surveillance - Foodborne Diseases Active Surveillance Network, 10 U.S. Sites, 2013-2016.

Authors:  Ellyn P Marder; Paul R Cieslak; Alicia B Cronquist; John Dunn; Sarah Lathrop; Therese Rabatsky-Ehr; Patricia Ryan; Kirk Smith; Melissa Tobin-D'Angelo; Duc J Vugia; Shelley Zansky; Kristin G Holt; Beverly J Wolpert; Michael Lynch; Robert Tauxe; Aimee L Geissler
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2017-04-21       Impact factor: 17.586

8.  Strategies for surveillance of pediatric hemolytic uremic syndrome: Foodborne Diseases Active Surveillance Network (FoodNet), 2000-2007.

Authors:  Kanyin L Ong; Mirasol Apostal; Nicole Comstock; Sharon Hurd; Tameka Hayes Webb; Stephanie Mickelson; Joni Scheftel; Glenda Smith; Beletshachew Shiferaw; Effie Boothe; L Hannah Gould
Journal:  Clin Infect Dis       Date:  2012-06       Impact factor: 9.079

9.  Section 2: AKI Definition.

Authors: 
Journal:  Kidney Int Suppl (2011)       Date:  2012-03

Review 10.  Treatment and outcome of Shiga-toxin-associated hemolytic uremic syndrome (HUS).

Authors:  Johanna Scheiring; Sharon P Andreoli; Lothar Bernd Zimmerhackl
Journal:  Pediatr Nephrol       Date:  2008-08-13       Impact factor: 3.714

View more
  8 in total

1.  Case definitions of hemolytic uremic syndrome following Escherichia coli O157:H7 infection vary in validity.

Authors:  Gillian A M Tarr; Hanna N Oltean; Amanda I Phipps; Peter Rabinowitz; Phillip I Tarr
Journal:  Int J Med Microbiol       Date:  2018-10-10       Impact factor: 3.473

Review 2.  Enterohemorrhagic Escherichia coli and a Fresh View on Shiga Toxin-Binding Glycosphingolipids of Primary Human Kidney and Colon Epithelial Cells and Their Toxin Susceptibility.

Authors:  Johanna Detzner; Gottfried Pohlentz; Johannes Müthing
Journal:  Int J Mol Sci       Date:  2022-06-21       Impact factor: 6.208

3.  Predicting Adverse Outcomes for Shiga Toxin-Producing Escherichia coli Infections in Emergency Departments.

Authors:  Chu Yang Lin; Jianling Xie; Stephen B Freedman; Ryan S McKee; David Schnadower; Phillip I Tarr; Yaron Finkelstein; Neil M Desai; Roni D Lane; Kelly R Bergmann; Ron L Kaplan; Selena Hariharan; Andrea T Cruz; Daniel M Cohen; Andrew Dixon; Sriram Ramgopal; Elizabeth C Powell; Jennifer Kilgar; Kenneth A Michelson; Martin Bitzan; Kenneth Yen; Garth D Meckler; Amy C Plint; Fran Balamuth; Stuart Bradin; Serge Gouin; April J Kam; James A Meltzer; Tracy E Hunley; Usha Avva; Robert Porter; Daniel M Fein; Jeffrey P Louie; Gillian A M Tarr
Journal:  J Pediatr       Date:  2021-01-05       Impact factor: 4.406

Review 4.  Roles of Shiga Toxins in Immunopathology.

Authors:  Moo-Seung Lee; Vernon L Tesh
Journal:  Toxins (Basel)       Date:  2019-04-09       Impact factor: 4.546

5.  Shiga toxin (Stx) type 2-induced increase in O-linked N-acetyl glucosamine protein modification: a new therapeutic target?

Authors:  Rebecca A Bova; Angela Melton-Celsa
Journal:  EMBO Mol Med       Date:  2021-12-22       Impact factor: 12.137

6.  Interventions for Shiga toxin-producing Escherichia coli gastroenteritis and risk of hemolytic uremic syndrome: A population-based matched case control study.

Authors:  Shota Myojin; Kyongsun Pak; Mayumi Sako; Tohru Kobayashi; Takuri Takahashi; Tomimasa Sunagawa; Norihiko Tsuboi; Kenji Ishikura; Masaya Kubota; Mitsuru Kubota; Takashi Igarashi; Ichiro Morioka; Isao Miyairi
Journal:  PLoS One       Date:  2022-02-04       Impact factor: 3.240

7.  [The postbiotic HM0539 from Lactobacillus rhamnosus GG prevents intestinal infection by enterohemorrhagic E. coli O157: H7 in mice].

Authors:  Hanyun Zhang; Jie Gao; Xiaolong He; Zelong Gong; Yu Wan; Tongtong Hu; Yubin Li; Hong Cao
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2020-02-29

Review 8.  AB5 Enterotoxin-Mediated Pathogenesis: Perspectives Gleaned from Shiga Toxins.

Authors:  Erika N Biernbaum; Indira T Kudva
Journal:  Toxins (Basel)       Date:  2022-01-16       Impact factor: 4.546

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.